Evaluation of the antibody response to the EBV proteome in EBV-associated classical Hodgkin lymphoma.
| Autor: | Liu Z; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD., Jarrett RF; MRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom., Hjalgrim H; Statens Serum Institut, Copenhagen, Denmark.; Department of Haematology, Rigshospitalet, Copenhagen, Denmark., Proietti C; Centre for Molecular Therapeutics, Australian Institute of Tropical Health & Medicine, James Cook University, Cairns, QLD, Australia., Chang ET; Stanford Cancer Institute, Stanford, CA.; Center for Health Sciences, Exponent, Inc., Menlo Park, CA., Smedby KE; Department of Medicine Solna, Division of Clinical Epidemiology, Karolinska Institutet, Stockholm, Sweden., Yu KJ; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD., Lake A; MRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom., Troy S; Centre for Molecular Therapeutics, Australian Institute of Tropical Health & Medicine, James Cook University, Cairns, QLD, Australia., McAulay KA; REPROCELL Europe Ltd., Glasgow, United Kingdom., Pfeiffer RM; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD., Adami HO; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.; Clinical Effectiveness Research Group, Institute of Health, University of Oslo, Oslo, Norway., Glimelius B; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden., Melbye M; Statens Serum Institut, Copenhagen, Denmark.; University of Copenhagen, Clinical Medicine, Copenhagen, Denmark.; Stanford University School of Medicine, Stanford, CA., Hildesheim A; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD., Doolan DL; Centre for Molecular Therapeutics, Australian Institute of Tropical Health & Medicine, James Cook University, Cairns, QLD, Australia., Coghill AE; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD.; Cancer Epidemiology Program, Division of Population Sciences, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | International journal of cancer [Int J Cancer] 2020 Aug 01; Vol. 147 (3), pp. 608-618. Date of Electronic Publication: 2019 Nov 14. |
| DOI: | 10.1002/ijc.32741 |
| Abstrakt: | The humoral immune response to Epstein-Barr virus (EBV) in classical Hodgkin lymphoma (cHL) stratified by EBV tumor status is unclear. We examined IgG and IgA antibody responses against 202 protein sequences representing 86 EBV proteins using a microarray and sera from 139 EBV-positive cHL cases, 70 EBV-negative cHL cases and 141 population-based controls frequency matched to EBV-positive cHL cases on sex and age by area (UK, Denmark and Sweden). We leveraged existing data on the proportion of circulating B-cells infected by EBV and levels of serum CCL17, a chemokine secreted by cHL tumor cells, from a subset of the cHL cases in the UK. Total IgG but not IgA response level was significantly different between EBV-positive cHL cases and controls. The distinct serological response included significant elevations in 16 IgG antibodies and 2 IgA antibodies, with odds ratios (© 2019 UICC.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|
Plný text